Nanexa doses the last patients with 30 mg liraglutide in the NEX-22-01 study
Nanexa announces that all patients have now been included in the fourth and final dose cohort in the Phase I study of NEX-22, a one-month formulation of liraglutide.
NEX-22 is a new promising treatment being developed for Type 2 diabetes. The Phase I study aims to evaluate the pharmacokinetics, safety, and tolerability of NEX-22. The inclusion of the last patients in the fourth dose cohort marks an important milestone in the development of this one-month liraglutide product.
"We are very pleased with the progress we have made in the Phase I study of NEX-22," says David Westberg, CEO of Nanexa. "The positive safety and tolerability evaluation of the first patient in the fourth dose cohort confirms that we can complete the study with the remaining patients as planned and take further steps towards offering a new treatment option for Type 2 diabetes patients."
These data will support the start of the next clinical study and strengthen the company's business activities, further underscoring the potential of NEX-22 as a new effective treatment.
